Scottish Enterprise signs MoU with CPI
As part of an event marking the start of construction of a new Oligonucleotide Manufacturing Centre of Excellence , Scottish Enterprise and CPI have entered into an agreement to formalise a shared ambition to help Scotland be a place where companies in key technology sectors thrive.
Breaking ground on a new Centre of Excellence is just one example of that ambition becoming reality, representing a terrific step towards Scotland becoming a world-renowned Oligonucleotide hub where innovative, life-saving treatments will be developed for patients around the globe.
It is one of several projects the two organisations have worked on in partnership in recent years, sitting alongside the Medicines Manufacturing Innovation Centre and further expanding the footprint at the Advanced Manufacturing Innovation District Scotland.
The Memorandum of Understanding (MoU) was signed by Adrian Gillespie, Chief Executive of Scottish Enterprise and Frank Millar CEO at CPI, and commits the organisations to work together to:
- increase business innovation activity in Scotland through the number and growth rate of companies
- transform the scale and reach of investment into Scottish companies
- raise the capacity and ambition of Scottish businesses so they can capitalise on international opportunities
- support partners in the provision of skills and training activity essential for growth in key areas
- create strategic innovation infrastructure investments
Contact Information
Wendy Fleming
Notes to editors
About CPI
We catalyse the adoption of advanced technologies and manufacturing solutions to benefit people, places and our planet.
We’re a pioneering social enterprise that accelerates the development, scale-up, and commercialisation of deep tech and sustainable manufacturing solutions. As a trusted partner of industry, academia, government, and the investment community, we develop next-generation pharmaceutical manufacturing innovations to help deliver tomorrow’s medicines, vaccines, and therapeutics.
We offer world-leading facilities, over £220m of innovation assets, and over 700 people. Our expertise in small molecules, biologics, oligonucleotides and complex medicines accelerates drug development and scale-up. We host the largest pool of RNA and Lipid Nanoparticle biomanufacturing experts in the UK and have expertise in a wide range of alternative drug delivery systems.
We believe that by working together, we can build a better collective future. As part of UK Government’s High Value Manufacturing Catapult, we facilitate transformation across industries.
Creating lasting global impact from the North of England and Scotland, we invest in people and disruptive technologies to invigorate economies, create circular supply chains and make our world a better place.
Let’s innovate together: www.uk-cpi.com
Team photo:
L‑R: Andrew Henderson (Life Sciences Team Leader at Scottish Enterprise); Becky Fields (Corporate Communications Manager at CPI); Paul Blakeman (Principal Strategic Partnerships Manager at CPI); Frank Millar (CEO of CPI); Arun Harish (Chief Strategy Officer at CPI); Adrian Gillespie (CEO at Scottish Enterprise); Bryan Fraser (Global Head of Business Development at Scottish Development International); Paul Foley (Senior Project Manager at Scottish Enterprise).